Stockholm Stock Exchange | Mid Cap
Bioarctic
+28.94%
Latest
-
3 months
Goldman SachsDNBRBCRX SecuritiesCarnegieKempenNordea MarketsDNB Markets

Price Targets For Bioarctic

AnalystPrice TargetDateUpside
Goldman Sachs278 SEKAug -24
+28.94%
DNB270 SEKAug -24
RBC290 SEKJul -24
RX Securities290 SEKJul -24
Carnegie370 SEKFeb -24
Kempen350 SEKNov -23
Nordea Markets356 SEKNov -22
DNB Markets250 SEKJul -21

About The Company

BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as “disease modifiers”. They affect the underlying disease pathology and can hopefully stop or significantly delay disease progression.
Bioarctic